PRQR vs LLY vs REGN vs NVO vs PFE vs KO vs JPM

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -19. 2% for ProQR Therapeutics N. V. (PRQR). Novo Nordisk A/S (NVO) offers the better valuation at 12. 3x trailing P/E (2. 0x forward), making it the more compelling value choice. Analysts rate ProQR Therapeutics N. V. (PRQR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novo Nordisk A/S (NVO) is the cheapest at 12.

3x versus Eli Lilly and Company at 49. 4x. On forward P/E, Novo Nordisk A/S is actually cheaper at 2. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novo Nordisk A/S wins at 0. 10x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.

1%, compared to -80. 6% for ProQR Therapeutics N. V. (PRQR). Over 10 years, the gap is even starker: LLY returned +1485% versus PRQR's -68. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus ProQR Therapeutics N. V. 's 1. 62β — meaning PRQR is approximately -908% more volatile than KO relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -19. 2% for ProQR Therapeutics N. V. (PRQR). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -11. 8% for ProQR Therapeutics N. V.. Over a 3-year CAGR, PRQR leads at 62. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus -265. 2% for ProQR Therapeutics N. V. — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -275. 9% for PRQR. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Novo Nordisk A/S (NVO) is the more undervalued stock at a PEG of 0. 10x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Novo Nordisk A/S (NVO) trades at 2. 0x forward P/E versus 30. 9x for Eli Lilly and Company — 28. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRQR: 152. 1% to $3. 63.

In this comparison, PFE (6.

6% yield), NVO (4. 1% yield), KO (2. 5% yield), JPM (1. 9% yield), REGN (0. 6% yield), LLY (0. 5% yield) pay a dividend. PRQR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1485% 10Y return). ProQR Therapeutics N. V. (PRQR) carries a higher beta of 1. 62 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1485%, PRQR: -68. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PRQR (Healthcare) and LLY (Healthcare) and REGN (Healthcare) and NVO (Healthcare) and PFE (Healthcare) and KO (Consumer Defensive) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PRQR is a small-cap quality compounder stock; LLY is a mega-cap high-growth stock; REGN is a mid-cap deep-value stock; NVO is a mid-cap deep-value stock; PFE is a mid-cap income-oriented stock; KO is a large-cap quality compounder stock; JPM is a large-cap deep-value stock. LLY, REGN, NVO, PFE, KO, JPM pay a dividend while PRQR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.